Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/28235Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Liew, David F L | - |
| dc.contributor.author | Robinson, Philip C | - |
| dc.date | 2021-11-15 | - |
| dc.date.accessioned | 2021-12-07T02:51:05Z | - |
| dc.date.available | 2021-12-07T02:51:05Z | - |
| dc.date.issued | 2021-11-15 | - |
| dc.identifier.citation | The Lancet. Rheumatology 2021; online first: 15 November | en |
| dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/28235 | - |
| dc.language.iso | eng | |
| dc.title | What does endemic COVID-19 mean for the future of rituximab? | en |
| dc.type | Journal Article | en |
| dc.identifier.journaltitle | The Lancet. Rheumatology | en |
| dc.identifier.affiliation | University of Queensland School of Clinical Medicine, Faculty of Medicine, Herston, QLD, Australia | en |
| dc.identifier.affiliation | Department of Medicine, University of Melbourne, Parkville, VIC, Australia | en |
| dc.identifier.affiliation | Rheumatology | en |
| dc.identifier.affiliation | Royal Brisbane & Women's Hospital, Metro North Hospital & Health Service, Herston, QLD, Australia | en |
| dc.identifier.affiliation | Clinical Pharmacology and Therapeutics | en |
| dc.identifier.doi | 10.1016/S2665-9913(21)00362-3 | en |
| dc.type.content | Text | en |
| dc.identifier.pubmedid | 34806035 | |
| local.name.researcher | Liew, David F L | |
| item.grantfulltext | none | - |
| item.openairetype | Journal Article | - |
| item.languageiso639-1 | en | - |
| item.fulltext | No Fulltext | - |
| item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
| item.cerifentitytype | Publications | - |
| crisitem.author.dept | Rheumatology | - |
| crisitem.author.dept | Clinical Pharmacology and Therapeutics | - |
| Appears in Collections: | Journal articles | |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.